{"id":229386,"date":"2026-01-20T01:46:26","date_gmt":"2026-01-20T07:46:26","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/01\/liraglutide-in-acute-minor-ischemic-stroke-or-high-risk-transient-ischemic-attack-with-type-2-diabetes-the-lamp-randomized-clinical-trial"},"modified":"2026-01-20T01:46:26","modified_gmt":"2026-01-20T07:46:26","slug":"liraglutide-in-acute-minor-ischemic-stroke-or-high-risk-transient-ischemic-attack-with-type-2-diabetes-the-lamp-randomized-clinical-trial","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/01\/liraglutide-in-acute-minor-ischemic-stroke-or-high-risk-transient-ischemic-attack-with-type-2-diabetes-the-lamp-randomized-clinical-trial","title":{"rendered":"Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack With Type 2 Diabetes: The LAMP Randomized Clinical Trial"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/liraglutide-in-acute-minor-ischemic-stroke-or-high-risk-transient-ischemic-attack-with-type-2-diabetes-the-lamp-randomized-clinical-trial2.jpg\"><\/a><\/p>\n<p>Liraglutide addition for Chinese patients with type 2 diabetes and minor AIS or high-risk TIA reduced 90-day stroke recurrence and improved functional outcomes.<\/p>\n<hr>\n<p>Question Do glucagon-like peptide\u20131 receptor agonists (liraglutide) reduce stroke recurrence in patients with type 2 diabetes who have minor acute ischemic stroke or high-risk transient ischemic attack?<\/p>\n<p><strong>Findings<\/strong> In this randomized clinical trial of 636 participants with type 2 diabetes, 25 patients (7.9%) who were randomly assigned to receive standard therapy plus liraglutide and 44 (13.8%) of those who received standard therapy had recurrent stroke at 90 days.<\/p>\n<p><strong>Meaning<\/strong> The results of this randomized clinical trial suggest that, compared with standard therapy, liraglutide might reduce recurrent stroke in patients with type 2 diabetes who had minor acute ischemic stroke or high-risk transient ischemic attack.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Liraglutide addition for Chinese patients with type 2 diabetes and minor AIS or high-risk TIA reduced 90-day stroke recurrence and improved functional outcomes. Question Do glucagon-like peptide\u20131 receptor agonists (liraglutide) reduce stroke recurrence in patients with type 2 diabetes who have minor acute ischemic stroke or high-risk transient ischemic attack? Findings In this randomized clinical [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-229386","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/229386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=229386"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/229386\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=229386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=229386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=229386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}